Follow-The-Filings

Security · featured owners

BCRX Biocryst Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.8%
  • $4M
  • 1 reduce 1 exit

BCRX (Biocryst Pharmaceuticals Inc.) is held in 1 featured 13F book as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (0.76%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.8% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel reduce 0.76%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 0.76% Reduce −7.0% 400,248 $4M history
Farallon Capital Management exited 2026 Q2 last 2026 Q1 <0.01% Exit 0.00% 24,000 $228K history

1 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 11 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K/A 2.05 Filing Doc
8-K 2.05,7.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
DEFA14A Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Aug 31, 2026 · 5 forms Filing Doc
4 Period Jun 11, 2026 · 9 forms Filing Doc
4 Period May 29, 2026 · 5 forms Filing Doc
4 Period May 18, 2026 Filing Doc
4 Period May 13, 2026 Filing Doc
4 Period Apr 6, 2026 Filing Doc
4 Period Mar 20, 2026 Filing Doc
4 Period Mar 16, 2026 Filing Doc
4 Period Feb 27, 2026 Filing Doc

Updated 8 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $331.41M $450.71M $874.84M
Gross profit * $326.93M $438.44M $855.76M
Gross margin * 98.6% 97.3% 97.8%
Net income -$226.54M -$88.88M $263.86M
Net margin * -68.4% -19.7% 30.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $495.97M $421.97M $404.35M
Total non-current assets * $20.99M $68.45M $109.81M
Total assets $516.96M $490.42M $514.16M
Total current liabilities $149.99M $160.38M $196.07M
Total non-current liabilities * — $805.97M $437.24M
Total equity -$455.53M -$475.93M -$119.15M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$95.14M -$52.02M $347.37M
Cash from investing -$131.5M $52.59M -$13.69M
Cash from financing $32.48M -$5.76M -$349.93M
Net change in cash -$193.79M -$6.12M -$14.99M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders